Monographie - Foscarnet sodium - Stabilis 4.0

zadnja posodobitev :
14/02/2025

Protivirusno zdravilo

Foscarnet sodium

Brizgalka

Stabilnost raztopine

Stabilnost mešanice

Faktorji, ki vplivajo na stabilnost

Kompatibilnost

način aplikacije

Viri

pdf

Kemična formula

Lastniško ime

Lastniško ime

Sestava pomožnih snovi je med paralelami lahko različna

Foscarnet	Argentina, Čile, Ekvador, Kolumbija, Mehika, Peru, Portugalska, Španija, Združene države Amerike
Foscavir	Avstralija, Avstrija, Belgija, Francija, Grčija, Italija, Luksemburg, Madžarska, Nemčija, Nizozemska, nova Zelandija, Španija, Švedska, Švica, Velika Britanija, Združene države Amerike

Viri

Brizgalka

Viri : Foscarnet sodium

	Tip	objava
2	časopis	Woods K, Steinmann W, Bruns L, Neels JT. Stability of foscarnet in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 88-90.
36	časopis	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
64	časopis	DiStefano JE, Outman WR. Additional data on visual compatibility of foscarnet sodium with morphine sulfate. Am J Hosp Pharm 1992 ; 49: 1672.
73	časopis	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
75	časopis	Mathew M, Das Gupta V, Bethea C. Stability of foscarnet sodium in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1994 ; 19: 35-36.
132	časopis	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
246	časopis	McDonald C, Boddy M, Garas G. The stability of foscarnet in the presence of potassium. Aust J Hosp Pharm 1996 ; 26: 560-561.
496	časopis	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Traduction Laboratorij	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	časopis	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
2262	časopis	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3595	Traduction Laboratorij	Aciclovir - Summary of Product Characteristics Hospira 2009
3662	Traduction Laboratorij	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014
3728	časopis	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3883	Traduction Laboratorij	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
4319	časopis	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.

Mentions Légales